ORMP Oramed Pharmaceuticals Inc.

5.01
+0.09  (+2%)
Previous Close 4.92
Open 4.66
Price To Book 5.22
Market Cap 89,118,762
Shares 17,788,176
Volume 165,419
Short Ratio
Av. Daily Volume 139,921
Stock charts supplied by TradingView

NewsSee all news

  1. Oramed to Present at BIO CEO & Investor Conference

    NEW YORK, Feb. 4, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced

  2. Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board

    NEW YORK, Jan. 30, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today

  3. Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

    NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  4. Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

    NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the

  5. Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board

    NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data noted 2/3 arms showed significant reductions. Data from second cohort due 1Q 2020.
ORMD-0801
Type 2 Diabetes
Phase 1 trial completed. Assessing options for future development.
ORMD-0901
Type 2 diabetes
Phase 2 data due 1Q 2020.
ORMD-0801
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Oramed to Present at BIO CEO & Investor Conference

    NEW YORK, Feb. 4, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced

  2. Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board

    NEW YORK, Jan. 30, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today

  3. Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

    NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  4. Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

    NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the

  5. Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board

    NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today

  6. Oramed Pharmaceuticals Issues Letter to Shareholders

    NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased

  7. Oramed Appoints Dr. Arie Mayer to Board of Directors

    NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today

  8. Oramed to Present a Scientific Poster at International Diabetes Federation Congress

    NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  9. Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

    NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced

  10. Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event

    NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted

  11. Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

    NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor

  12. Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes

    NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced

  13. Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference

    NEW YORK, Sept. 18, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  14. Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

    NEW YORK, Sept. 17, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the

  15. Oramed to Present at Three Upcoming Conferences

    NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today